SCHEMBL2813052

SCHEMBL2813052

CN(C(=O)C1CN(Cc2ccccc2)c2nc(NCc3ccccc3)nc3[nH]nc1c23)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CACNA1G O43497 6/20 0.38
CACNA1H O95180 6/20 0.38
CACNA1I Q9P0X4 6/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
GAA P10253 2/20 0.37
MEN1 O00255 2/20 0.37
PTAFR P25105 1/20 0.35
BRS3 P32247 1/20 0.35
CCR5 P51681 2/20 0.35
BACE1 P56817 1/20 0.34
ATM Q13315 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
HTT P42858 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL538332 0.83 CACNA1G (0.39) KMT2ANPC1RAB9ACACNA1GCACNA1H
SCHEMBL538002 0.79 KDM1A (0.41) CACNA1GCACNA1HCACNA1I
SCHEMBL538580 0.79 CACNA1G (0.41) KMT2ACACNA1GCACNA1HCACNA1ISMN1; SMN2
SCHEMBL2811162 0.79 USP2 (0.39) CACNA1GCACNA1HCACNA1IALDH1A1
SCHEMBL2814282 0.79 KMT2A (0.42) KMT2ARAB9ACACNA1GCACNA1HCACNA1I
SCHEMBL2811925 0.78 CACNA1G (0.42) CACNA1GCACNA1HCACNA1IALDH1A1
SCHEMBL2815942 0.78 MC4R (0.43) NPC1RAB9ACACNA1GCACNA1HCACNA1I
SCHEMBL2813056 0.77 KMT2A (0.37) KMT2ANPC1RAB9ACACNA1GCACNA1H
SCHEMBL2812233 0.77 HTT (0.41) KMT2ACACNA1GCACNA1HCACNA1ISMN1; SMN2
SCHEMBL2812033 0.76 P2RX7 (0.42) KMT2ACACNA1GCACNA1HCACNA1IMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 KMT2A 2836/4885NPC1 701/4885RAB9A 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.